1. Introduction

   • P. Rondot

   EditorialNotes Pages: S1 - S1

2. Parkinson's disease: pathological mechanisms and actions of piribedil

   • Peter Jenner

   OriginalPaper Pages: S2 - S8

3. Deterioration of dopaminergic pathways and alterations in cognition and motor functions

   • B. Dubois
   • B. Pillon
   • Y. Agid

   OriginalPaper Pages: S9 - S12

4. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil

   • Hélène Ollat

   OriginalPaper Pages: S13 - S16

5. Retinal dopaminergic receptor affinity and ocular pharmacokinetic profile of piribedil

   • P. Lapalus
   • P. Denis
   • P. P. Elena

   OriginalPaper Pages: S17 - S21

6. Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects

   • C. Corbe
   • F. Arnaud
   • C. Janiak-Bolzinger

   OriginalPaper Pages: S22 - S27

7. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study

   • P. Rondot
   • M. Ziegler

   OriginalPaper Pages: S28 - S34